crc-22-0259-s03.pdf (27.81 kB)
Figure S3 from Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia
journal contributionposted on 2023-04-04, 02:05 authored by Kazuharu Kamachi, Hiroshi Ureshino, Tatsuro Watanabe, Nao Yoshida-Sakai, Yuki Fukuda-Kurahashi, Kazunori Kawasoe, Toshimi Hoshiko, Yuta Yamamoto, Yuki Kurahashi, Shinya Kimura
Figure S3. BCL2 and BCL-xL levels in HL60 and KG1a following Vehicle (Cont), 1.0 mM of OR21 (OR1), 0.1 mM (HL60) or 0.5 mM (KG1a) of venetoclax and OR21 and venetoclax (OR+Ven) combination treatment. n.s. indicated not significant.